Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.…
BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Senseonics Holdings (NASDAQ: SENS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 130 employees.
The shares were at 8.020 USD on 20 November 2026, up 33.4% over 52 weeks. Its 52-week range is 4.790 USD to 13.98 USD: the price is 42.6% below the high and 67.4% above the low.
Its market capitalisation is 439.34M USD.
Senseonics Holdings reports return on equity of -113.2%, an operating margin of -201.0% and revenue up 141.6% year over year.
It holds more cash than debt, a net cash position of 63.79M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 15.08 USD is 88.1% above the current price. The next earnings report is expected on 1 March 2027.